We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTR icon
101
Avantor
AVTR
$7.35B
$20.9M 0.21%
512,216
– –
AMWL icon
102
American Well
AMWL
$216M
$19.4M 0.2%
106,392
-696
-0.6% -$151K
TMDX icon
103
Transmedics
TMDX
$2.55B
$19.2M 0.2%
581,029
-148,960
-20% -$4.55M
ONEM
104
DELISTED
1Life Healthcare
ONEM
$16.9M 0.17%
836,190
– –
LEGN icon
105
Legend Biotech
LEGN
$4.57B
$14.5M 0.15%
286,556
-103,607
-27% -$4.31M
QTTB icon
106
Q32 Bio
QTTB
$339M
$13.7M 0.14%
96,507
– –
CVS icon
107
CVS Health
CVS
$137B
$13.5M 0.14%
158,548
-1,600
-1% -$134K
ZLAB icon
108
Zai Lab
ZLAB
$2.28B
$13.2M 0.13%
125,000
+3,000
+2% +$431K
WVE icon
109
Wave Life Sciences
WVE
$1.11B
$12.8M 0.13%
2,602,858
– –
LH icon
110
Labcorp
LH
$23.1B
$12.4M 0.13%
51,332
+9,195
+22% +$2.32M
PRVA icon
111
Privia Health
PRVA
$3.31B
$12.4M 0.13%
525,000
– –
NEUE
112
DELISTED
NeueHealth
NEUE
$12.2M 0.12%
18,750
– –
OSCR icon
113
Oscar Health
OSCR
$8.9B
$11.8M 0.12%
679,952
-14,184
-2% -$241K
NBP
114
NovaBridge Biosciences American Depositary Shares
NBP
$207M
$11.8M 0.12%
162,957
-20,500
-11% -$1.48M
GILD icon
115
Gilead Sciences
GILD
$166B
$11M 0.11%
157,000
+46,000
+41% +$3.23M
INGN icon
116
Inogen
INGN
$171M
$10.4M 0.11%
242,174
-38,689
-14% -$2.38M
GTH
117
DELISTED
Genetron Holdings Limited ADS
GTH
$10M 0.1%
241,046
– –
XRAY icon
118
Dentsply Sirona
XRAY
$2.74B
$9.24M 0.09%
159,129
– –
SGEN
119
DELISTED
Seagen Inc. Common Stock
SGEN
$9.07M 0.09%
53,400
+25,900
+94% +$4.03M
BNR
120
Burning Rock Biotech
BNR
$104M
$8.76M 0.09%
48,989
– –
ONC
121
BeOne Medicines Ltd
ONC
$32.5B
$8.35M 0.08%
23,000
-61,300
-73% -$20M
NPCE icon
122
Neuropace
NPCE
$541M
$8.05M 0.08%
507,930
– –
CELL
123
DELISTED
PhenomeX Inc. Common Stock
CELL
$7.53M 0.08%
385,014
– –
AMGN icon
124
Amgen
AMGN
$198B
$7.22M 0.07%
33,950
-95,630
-74% -$22M
GKOS icon
125
Glaukos
GKOS
$9.22B
$6.93M 0.07%
143,870
-351,562
-71% -$19.5M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.